The global sales of attenuated vaccines is estimated to be worth USD 5,068.2 million in 2024 and anticipated to reach a value of USD 9,693.9 million by 2034. Sales are projected to rise at a CAGR of 6.8% over the forecast period between 2024 and 2034. The revenue generated by Attenuated Vaccines in 2023 was USD 4,750.0 million. The industry is anticipated to exhibit a Y-o-Y growth of 6.7% in 2024.
The attenuated vaccines are live viruses or bacteria that are weakened in nature and, therefore, could not cause an illness in healthy people. These types of vaccines help the immune system recognize what the real pathogen is and protect against it.
They have widely been utilized in preventing diseases like measles, mumps, and rubella through the MMR vaccine, chicken pox, yellow fever, among others. Among these advantages, the protection levels given by them are usually very high after a single or two shots since it provokes antibody production and cellular immune defenses.
These vaccines are live but weakened in nature, and they are not advised to people with any forms of weakened states of immunity. The attenuated vaccines tend to do a great job in containing infectious diseases and improving the nation's health.
Global Attenuated Vaccines Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 4,750.0 million |
| Estimated Size, 2024 | USD 5,068.2 million |
| Projected Size, 2034 | USD 9,639.9 million |
| Value-based CAGR (2024 to 2034) | 6.7% |
The attenuated vaccines are produced with weakened, live pathogens that cannot cause any disease in a person with normal immunity. It give the immune system a strongly and long protection due to a close resemblance to natural infection. These vaccines play a considerable role in medical practice, as it protects individuals against infectious diseases such as measles, mumps, chickenpox, and yellow fever.
It often provides long-term protection only after one or two doses. They are particularly effective in inducing antibody production and cellular immune responses, which makes them useful in large-scale immunization programs for the control of infectious diseases. Beyond health, attenuated vaccines find their application in veterinary medicine for animal protection and in cancer immunotherapy, whereby they give an immune boost to target tumors.
The forecast period anticipates substantial growth in the attenuated vaccines industry, with an incremental opportunity of USD 4,625.7 million. Projections indicate that the market will expand to 2.0 times its current value by 2034.
Recent advent in technological development in vaccine manufacturing and the growing focus of manufacturers on launch of new products to the market anticipates the market growth. For instance, in May 2024, Takeda Pharmaceuticals received prequalification from the World Health Organization (WHO) for its TAK-003 candidate.
TAK-003, is a live-attenuated dengue vaccine developed by the company for children aged between 6 and 16 years.
In addition, increasing investments in research and development towards vaccine manufacturing further anticipates towards market growth. For instance, October 2023, the USA Department of Health and Human Services selected next-generation vaccine candidates for phase 2 clinical trials which has inclusion of Codagenix, a live attenuated intranasal vaccine candidate.
The company developing this candidate has received award of USD 10 million as a support for phase 2b clinical evaluation.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Comparative analysis of fluctuations in compound annual growth rate (CAGR) for the global attenuated vaccines market between 2023 and 2024 on six months basis is shown below. By this examination, major variations in the performance of these markets are brought to light, and also trends of revenue generation are captured hence offering stakeholders useful ideas on how to carry on with the market's growth path in any other given year.
January through June covers the first part of the year called half1 (H1), while half2 (H2) represents July to December
The table presents the expected CAGR for the global attenuated vaccines market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.5%, followed by a slightly slower growth rate of 7.2% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.5% (2023 to 2033) |
| H2 | 7.2% (2023 to 2033) |
| H1 | 6.8% (2024 to 2034) |
| H2 | 6.3% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 6.8% in the first half and increase moderately at 6.3% in the second half. In the first half (H1) the market witnessed a decrease of 70 BPS while in the second half (H2), the market witnessed a decrease of 90 BPS.
Growing Awareness for Immunization Surges the Growth of Attenuated Vaccines Market
Increased awareness for immunization has significantly affected the demand for attenuated vaccines, which confer complete and long-term immunity against a variety of infectious diseases. Awareness of vaccines, particularly through global campaigns by organizations such as the WHO and UNICEF, creates awareness among people for reliable methods of immunization.
Attenuated vaccines have greater recognition for their competence in eliciting strong and long-lasting immune responses and, hence, are preferred in both developed and developing regions. The awareness has increased particularly from recent pandemics like COVID-19, which put the need for vaccines.
The medical facilities has also played a significant role in raising awareness about the vaccination programs as they are important sources of information, offering them the access as well. The initiatives taken by medical facilities for raising awareness of vaccination includes vaccination drives and outreach programs that bring vaccines right into the communities, most especially in the underserved areas.
Therefore, the communal activities undertaken by healthcare facilities in collaboration with pharmaceutical companies and international non-government organization for raising awareness of vaccination for prevention of several diseases anticipates the growth of the market.
Adoption of New Techniques for Attenuation can Aid Manufacturers to Stay Competitive
Advanced techniques involved, such as genetic engineering, codon deoptimization, and reverse genetics, give the edge in the market to the vaccine manufacturers. Genetic engineering make the attenuated vaccines much safer and precise in their actions, making it possible to selectively delete virulence factors in target organisms.
These factor make the vaccines more effective without the possibility of return to a more virulent form. Techniques such as codon deoptimization further accelerate vaccine development by controlling pathogen replication and, hence, give the companies a head start in fast responses to emerging diseases. Use of this advancements help manufacturers in rapid vaccine development and aid them to stand out and hold leading positions in the market.
Besides, other technique such as reverse genetics allows for rapid tailoring of vaccines against mutating strains of pathogens and helps the manufacturers stay ahead of the mutations of diseases. These methods enhance the production efficiency that cuts on the overall cost and allows large-scale manufacturing, hence the companies can meet the global demand at a competitive price.
Such innovations open doors to wider vaccination possibilities for more diseases, including cancer. Therefore, introduction of advanced manufacturing techniques that allow for the creation of safer, more effective, and scalable vaccines critical to long-term competitiveness in the market.
Growing Emphasis Towards Development and Use of New Vaccine Platform Technology
New vaccine platform technologies are revolutionizing vaccine development and helping manufacturers overcome traditional challenges. Innovation in mRNA vaccine platforms-as witnessed has allowed for rapid design and production. These mRNA sequences synthesized in the lab, circumvents the lengthier process required to grow viruses.
This enable manufacturers to quickly adapt vaccines to a new pathogen or another variant of the virus by reducing development time. Other advantages of the viral vector platform are the use of vectors with extensive working and safety records, such as adenovirus vectors, to carry genetic material from novel pathogens. Such reutilization quickens the pace of development.
DNA vaccines also minimize the level of complexity in their preparation process due to the reliance on pathogen-specific gene insertion into host cells, thereby dispensing with the use of live pathogens in the production process.
Synthetic biology and modular platforms allow for a "plug-and-play" approach where the core vaccine structure can remain unchanged but the antigenic component can be changed out in a rapid manner to target the pathogens. In effect, the flexibility afforded by these technologies allows for the immediate response in the case of new health threats, like pandemics.
Taken together, these technologies allow manufacturers to improve efficiency while responding faster to the challenges of global health. Therefore, researchers are continuously working towards development of new vaccine platform technologies.
For instance, according to an article published by KU LEUVEN in June 2021, researchers have developed a next-generation vaccine platform technology which aids manufacturers to design and produce a high yield thermostable infectious disease. The technology is named PLLAV (Plasmid Launched Live Attenuated Virus) vaccine which consist of a multi-host and easy-to-produce high quantities of bacterial artificial chromosomes.
Storage and Stability Concerns Associated with Attenuated Vaccines Restrains its Growth in the Market
Live attenuated vaccines are manufactured from weakened forms of pathogens, which are susceptible to temperature conditions. These have to be stored under strict conditions within a narrow range, from 2°C to 8°C, to prevent degradation. If not stored correctly, the attenuated virus or bacteria could lose their potency; resulting, into the ineffectiveness of the vaccine.
Additional cold-chain requirements add yet another barrier to costly distribution and storage. The length of special equipment required involves continuous monitoring of the correct temperature in all stages of the supply chain, from transport to storage and handling. Even short breaks compromise quality in cold chain management.
Therefore, live attenuated vaccines have remained unadopted for many healthcare providers and governments, especially in settings that are remote or resource-constrained and with difficult conditions to build such infrastructure.
These same issues of stability also significantly reduce the shelf life of the vaccines compared with other vaccine types, such as inactivated or subunit vaccines. This short shelf life translates into more wasted stockpiles on average for attenuated vaccines, increasing overall costs to health systems and complicating the logistics of large vaccination campaigns.
Because of these logistical barriers, health organizations may be more reluctant to recommend attenuated vaccines. Thus, due to storage and stability issues with attenuated vaccines, their wide applications are affected, and market growth is restricted across the globe.
Principal Consultant
The global attenuated vaccines industry recorded a CAGR of 6.7% during the historical period between 2019 and 2023. The growth of attenuated vaccines industry was positive as it reached a value of USD 4,750.0 million in 2023 from USD 3,358.1 billion in 2019.
Attenuated vaccines, represent living pathogens attenuated to a point where they no longer cause infections in healthy people. These vaccines imitate natural infections and generate excellent, long-lasting immunity, equating to good efficacy. Attenuated vaccines such as MMR, polio-oprv, and yellow fever have achieved significant growth rates because of their very broad application in global immunization programs.
Besides government requirements, initiatives by organizations such as WHO and UNICEF have provided the widespread vaccination programs. These vaccines have gained popularity owing to their large-scale immunity achieved with fewer doses of attenuated vaccine. These vaccines have also served as a cornerstone for infectious disease control and have formed the basis for global smallpox eradication.
Technologies like reverse genetics and synthetic biology today allow precision in the attenuation process with reduced risks of reversion to virulence. Further, a range of viral vector platforms led to the development of new attenuated vaccines against emerging diseases such as Ebola, and Zika.
Improvements in thermostability are also overcoming long-standing storage issues, which enable these vaccines to remain potent at higher temperatures. The strong immune response provided by these vaccines makes them a key towards preparedness against pandemics. Few of these vaccines are also under investigation in cancer gene therapy and personalized medicine.
Innovations in delivery techniques of attenuated vaccines, such as microneedle patches, efforts and initiatives across the world to eradicate diseases such as polio and measles will continue to keep demand for attenuated vaccines at a sustainable level.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 56.4% in global market. These market leaders are characterized by high production capacity and a wide product portfolio.
These market leaders are distinguished by their extensive expertise in manufacturing and reconditioning across multiple packaging formats and a broad geographical reach, underpinned by a robust consumer base. Prominent companies within tier 1 include Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., and Sanofi.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 28.7% market share. These are characterized by a strong presence overseas and strong market knowledge. Prominent companies in tier 2 include Astellas Pharma, and Johnson & Johnson including few others.
Finally, Tier 3 companies, such as CSL Limited, and Serum Institute of India Pvt. Ltd., are essential for the market. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the attenuated vaccines market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, with a value share of 87.7% through 2034. In Asia Pacific, South Korea is projected to witness a CAGR of 5.6% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| Canada | 3.4% |
| Argentina | 2.4% |
| France | 4.4% |
| Russia | 3.8% |
| India | 5.6% |
| South Korea | 4.2% |
| GCC Countries | 6.1% |
USA attenuated vaccines market is poised to exhibit a CAGR of 3.1% during the forecast period. Currently, it holds the highest share in the North American market, and the trend is expected to continue during the forecast period.
The USA has a robust immunization programs, facilitated through federal and state governments. These immunization programs greatly facilitate easy access to attenuated vaccines, and aid individuals in prevention, against diseases. Vaccination programs such as, the VFC program has been facilitating the provision of free vaccines to all eligible children seen in private or public sites.
In addition, policies mandating the vaccination for school entry and healthcare settings are major drivers of high vaccination rates in the USA Moreover, initiatives taken by government for raising public awareness and education also help further for the growth of the market in the USA Therefore, the programs undertaken by government authorities ensuring high immunization coverage, and prevention of resurgence of the disease, support ongoing growth of attenuated vaccines in USA
China currently holds an optimum share of the attenuated vaccine industry. Chinese attenuated vaccine market is anticipated to grow at a CAGR of 4.8% throughout the forecast period.
The huge and fast-expanding market of China provides a golden opportunity for access to the large and diversified population. Cost-effective production avenues can also be explored in collaboration with Chinese companies, since the lower labor and production cost in China contribute to reduction in the overall manufacturing cost.
These factors aid manufacturers to introduce their product to the international market at a more competitive price. Additionally, China's huge manufacturing capacity and experience in international markets enable international companies to scale up their production processes to fulfill demand efficiently.
These factors attracts huge number of international players to collaborate with Chinese manufacturers. For instance, in August 2023, AstraZeneca collaborated with CanSino Biologics, and signed a vaccine manufacturing deal. CanSino has planned to use its mRNA manufacturing platform and support AstraZeneca on R&D of certain vaccines.
These strategic partnerships strengthen global networks and enhance market positioning, opening up more opportunities for further expansions and collaborations. Therefore, working with Chinese vaccine manufacturers allows international firms to increase their presence in that market, decrease their costs, and speed up the development and distribution of vaccines which ultimately augments the market growth in the country.
Germany is expected to have a strong foothold when it comes to technology innovation. In 2023 the country is projected to account a significant share of the Attenuated Vaccines Market.
The strong biomedical research orientation in Germany, supported by leading institutions and universities, advances the technology of vaccines. This research improves vaccine safety by reducing the risks of reversion to virulence and enhances efficacy, making vaccines suitable for a wider range of populations.
Germany’s current research and development institutes develops new attenuated vaccines for combating diseases of emerging and re-emerging nature. For instance, in April 2023, a team of scientists at Berlin research institution has demonstrated a live SARS-CoV-2 vaccine in the journal Nature Microbiology. This vaccine has superior efficacy as compared to intramuscularly administered vaccines.
Therefore, the overall research efforts played by Germany serve to advance not just the science but also the safety and efficacy of attenuated vaccines for their increased growth and to meet future challenges in health. This are few of the factors that are significantly contributing to the growth of the market.
The section contains information about the leading segments in the industry. By vaccine type, the monovalent attenuated vaccines segment is estimated to grow at a CAGR of 3.5% throughout 2034.
| Vaccines Type | Monovalent Attenuated Vaccines |
|---|---|
| Value Share (2024) | 54.6% |
Monovalent weakened vaccines hold the greatest share in attenuated vaccines due to their focused approach towards combating particular pathogens, enhancing their efficiency and usage rate. A monovalent vaccine is prepared to have power against only one disease-causing organism.
This, in turn, allows for a much stronger and more targeted response from the immune system, given that the vaccine targets a single antigen. Furthermore, monovalent vaccines preclude the potential for antigen interference that might occur with multivalent vaccines, thus ensuring a more predictable immune response.
Cost-effective production for monovalent vaccines, due to their lower resource requirements and fewer complicating factors during the manufacturing process, results in their desirability and enhanced market position. These advantages contribute to their strong market presence and continued growth prospects.
It is also expected that further advancement in vaccine technology and manufacturing processes will improve efficacy and availability, maintaining their stronghold in worldwide immunization strategies for continued future growth.
| End Use | Hospitals |
|---|---|
| Value Share (2034) | 35.4% |
The hospitals segment is forecast to account for a revenue of majority of the share in the end users segment.
The rising burden of disease coupled with outbreaks of vaccine-preventable diseases-measles, mumps, and rubella, or MMR-have ramped up needs for effective vaccination strategies in hospitals. As attenuated vaccines are mainly involved in providing better immunity for a longer period, they are considered more often to prevent such types of diseases and infection controls.
Growing awareness and recommendations of public health guidelines are also contributing to the growth of attenuated vaccines in hospitals. Improvements in vaccine technology and manufacturing, such as increased stability and safety, also contribute to making the vaccines more adaptable for hospital use.
Coupled with increasing focus on preventive care and infection control, these developments together portend a bright future as far as demand for attenuated vaccines is concerned. With increased emphasis by hospitals on patient safety and prevention of diseases, the role of attenuated vaccines will continue to increase, thereby furthering their market growth and acceptance into healthcare.
Substantial investments are seen in the attenuated vaccines industry towards research and development in order to drive innovations. Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence.
Recent Industry Developments in Attenuated Vaccines Market
In terms of vaccines type, the industry is divided into monovalent attenuated vaccines, and multivalent attenuated vaccines.
In terms of indication, the industry is segregated into attenuated vaccines for influenza, attenuated vaccines for measles, mumps & rubella (MMR), attenuated vaccines for polio, attenuated vaccines for chickenpox, attenuated vaccines for shingles, attenuated vaccines for rotavirus and attenuated vaccines for other indications.
In terms of route of administration, the industry is segregated into intramuscular attenuated vaccines administration, subcutaneous attenuated vaccines administration, oral attenuated vaccines administration, and intranasal attenuated vaccines administration
In terms of age group, the industry is segregated into attenuated vaccines for pediatrics, attenuated vaccines for adolescents, attenuated vaccines for adults and attenuated vaccines for geriatric patients
The industry is classified by end user as attenuated vaccines for hospitals, attenuated vaccines for clinics and attenuated vaccines for other end users.
Key countries of North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa (MEA) have been covered in the report.
The global attenuated vaccines industry is projected to witness CAGR of 6.7% between 2024 and 2034.
The global attenuated vaccines industry stood at USD 4,750.0 million in 2023.
The global attenuated vaccines industry is anticipated to reach USD 9,693.9 million by 2034 end.
India is set to record the highest CAGR of 5.6% in the assessment period.
The key players operating in the global attenuated vaccines industry include Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Sanofi, Astellas Pharma, Johnson & Johnson, CSL Limited, Serum Institute of India Pvt. Ltd.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. By Vaccines Type 5.2. By Indication 5.3. By Route of Administration 5.4. By Age Group 5.5. By End User 5.6. By Region 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Vaccines Type 6.1. Monovalent Attenuated Vaccines 6.2. Multivalent Attenuated Vaccines 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Indication 7.1. Attenuated Vaccines for Influenza 7.2. Attenuated Vaccines for Measles, Mumps & Rubella (MMR) 7.3. Attenuated Vaccines for Polio 7.4. Attenuated Vaccines for Chickenpox 7.5. Attenuated Vaccines for Shingles 7.6. Attenuated Vaccines for Rotavirus 7.7. Attenuated Vaccines for Other Indications 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration 8.1. Intramuscular Attenuated Vaccines Administration 8.2. Subcutaneous Attenuated Vaccines Administration 8.3. Oral Attenuated Vaccines Administration 8.4. Intranasal Attenuated Vaccines Administration 8.5. Intravenous Attenuated Vaccines Administration 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Age Group 9.1. Attenuated Vaccines for Pediatrics 9.2. Attenuated Vaccines for Adolescents 9.3. Attenuated Vaccines for Adults 9.4. Attenuated Vaccines for Geriatric Patients 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User 10.1. Attenuated Vaccines for Hospitals 10.2. Attenuated Vaccines for Clinics 10.3. Attenuated Vaccines for Other End Users 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 11.1. North America 11.2. Latin America 11.3. East Asia 11.4. South Asia and Pacific 11.5. Western Europe 11.6. Eastern Europe 11.7. Middle East and Africa 12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 19. Sales Forecast 2024 to 2034 by Product, Origin, and Application for 30 Countries 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 21. Company Profile 21.1. Merck & Co., Inc. 21.2. GlaxoSmithKline plc 21.3. Pfizer Inc. 21.4. Sanofi 21.5. Astellas Pharma 21.6. Johnson & Johnson 21.7. CSL Limited 21.8. Serum Institute of India Pvt. Ltd.
Explore Healthcare Insights
View Reports
Attenuated Vaccines Market
